A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy

Trial Profile

A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Cabozantinib (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms METEOR
  • Sponsors Exelixis
  • Most Recent Events

    • 02 Aug 2017 According to an Exelixis media release, data will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
    • 27 Jun 2017 This trial has been completed in Czech Republic.
    • 19 Jun 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top